CO5300398A1 - Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek - Google Patents
Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mekInfo
- Publication number
- CO5300398A1 CO5300398A1 CO00053304A CO00053304A CO5300398A1 CO 5300398 A1 CO5300398 A1 CO 5300398A1 CO 00053304 A CO00053304 A CO 00053304A CO 00053304 A CO00053304 A CO 00053304A CO 5300398 A1 CO5300398 A1 CO 5300398A1
- Authority
- CO
- Colombia
- Prior art keywords
- alkyl
- cycloalkyl
- hydrogen
- optionally contains
- hydroxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Physical Education & Sports Medicine (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- AIDS & HIV (AREA)
- Nutrition Science (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Tropical Medicine & Parasitology (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
Abstract
Un método para tratar el dolor crónico, dicho método comprende administrar a un individuo que necesita dicho tratamiento una composición que comprende un inhibidor MEK seleccionado de un compuesto que se define en la Fórmula I<EMI FILE="00053304_1" ID="1" IMF=JPEG >donde:R1 es hidrógeno, hidroxi, alquilo de C1-C8, alcoxi de C1-C8, halo, trifluorometilo, o CN;R2 es hidrógeno;R3, R4, y R5 son independientemente hidrógeno, hidroxi, halo, trifluorometilo, alquilo de C1-C8, alcoxi de C1-C8, nitro, CN, o (O o NH)m -(CH2)n-R9, donde R9 es hidrógeno, hidroxi, CO2H, o NR10R11;n es 0-4;m es 0 ó 1;R10 y R11 son independientemente hidrógeno o alquilo de C1-C8, o tomados juntos con el nitrógeno al que están unidos pueden completar un anillo cíclico de 3-10 miembros que opcionalmente contienen 1, 2, o 3 heteroátomos adicionales seleccionados de O, S, NH, o alquilo de N-C1-C8; O ||R6 es hidrógeno, alquilo de C1-C8, alquilo de C -C1-C8 arilo, aralquilo o cicloalquilo de C3-C10;R7 es hidrógeno, alquilo de C1-C8, alquenilo de C2-C8, alquinilo de C2-C8, cicloalquilo de C3-C10, (cicloalquilo o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9);y donde cualquiera de los grupos alquilo, alquenilo, y alquinilo que anteceden pueden ser no sustituidos o sustituidos por cicloalquilo (o cicloalquilo que opcionalmente contiene un heteroátomo seleccionado de O, S, o NR9), arilo, ariloxi, heteroarilo, o heteroariloxi; o R6 y R7 tomados juntos con el N-O al que están unidos pueden completar un anillo cíclico de 5 a 10 miembros, que opcionalmente contiene uno, dos o tres heteroátomos adicionales seleccionados de O, S, o NR10R11.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14429299P | 1999-07-16 | 1999-07-16 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO5300398A1 true CO5300398A1 (es) | 2003-07-31 |
Family
ID=22507940
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CO00053304A CO5300398A1 (es) | 1999-07-16 | 2000-07-14 | Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP1202726A2 (es) |
| JP (1) | JP2003504400A (es) |
| KR (1) | KR20020012315A (es) |
| CN (1) | CN1373660A (es) |
| AR (1) | AR024732A1 (es) |
| AU (1) | AU5786000A (es) |
| CA (1) | CA2374052A1 (es) |
| CO (1) | CO5300398A1 (es) |
| HU (1) | HUP0202623A3 (es) |
| IL (1) | IL147619A0 (es) |
| NZ (1) | NZ515567A (es) |
| PE (1) | PE20010545A1 (es) |
| PL (1) | PL352684A1 (es) |
| TR (1) | TR200200082T2 (es) |
| WO (1) | WO2001005392A2 (es) |
| ZA (1) | ZA200109907B (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU230251B1 (hu) | 2000-07-19 | 2015-11-30 | Warner-Lambert Co. | 4-Jód-fenil-amino-benzhidroxámsav-észter-származékok és ezeket tartalmazó gyógyászati készítmények |
| NZ518726A (en) | 2001-05-09 | 2004-06-25 | Warner Lambert Co | Method of treating or inhibiting neutrophil chemotaxis by administering a mek inhibitor |
| US7235537B2 (en) | 2002-03-13 | 2007-06-26 | Array Biopharma, Inc. | N3 alkylated benzimidazole derivatives as MEK inhibitors |
| PL401637A1 (pl) | 2002-03-13 | 2013-05-27 | Array Biopharma Inc. | N3 alkilowane pochodne benzimidazolu jako inhibitory MEK |
| US7632866B2 (en) | 2002-10-21 | 2009-12-15 | Ramot At Tel Aviv University | Derivatives of N-phenylanthranilic acid and 2-benzimidazolone as potassium channel and/or neuron activity modulators |
| ATE442847T1 (de) | 2003-07-24 | 2009-10-15 | Warner Lambert Co | Benzimidazol-derivate als mek-hemmer |
| US7144907B2 (en) | 2003-09-03 | 2006-12-05 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| US7538120B2 (en) | 2003-09-03 | 2009-05-26 | Array Biopharma Inc. | Method of treating inflammatory diseases |
| CA2542012A1 (en) * | 2003-10-08 | 2005-04-21 | Teijin Pharma Limited | A method for producing aminopyrrolidine derivatives and intermediate compounds |
| EP1682495A1 (en) | 2003-10-21 | 2006-07-26 | Warner-Lambert Company LLC | Polymorphic form of n- (r)-2,3-dihydroxy-propoxy -3,4-d ifluoro-2-(2-fluoro-4-iodophenylamino)-benzamide |
| WO2005051302A2 (en) | 2003-11-19 | 2005-06-09 | Array Biopharma Inc. | Bicyclic inhibitors of mek and methods of use thereof |
| US7732616B2 (en) | 2003-11-19 | 2010-06-08 | Array Biopharma Inc. | Dihydropyridine and dihydropyridazine derivatives as inhibitors of MEK and methods of use thereof |
| US7517994B2 (en) | 2003-11-19 | 2009-04-14 | Array Biopharma Inc. | Heterocyclic inhibitors of MEK and methods of use thereof |
| CN1882347A (zh) | 2003-11-21 | 2006-12-20 | 阿雷生物药品公司 | Akt蛋白激酶抑制剂 |
| MY144232A (en) * | 2004-07-26 | 2011-08-15 | Chugai Pharmaceutical Co Ltd | 5-substituted-2-phenylamino benzamides as mek inhibitors |
| EP1967516B1 (en) | 2005-05-18 | 2009-11-04 | Array Biopharma, Inc. | 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as MEK inhibitors for the treatment of hyperproliferative diseases |
| BRPI0617165B1 (pt) | 2005-10-07 | 2023-10-03 | Exelixis Inc | Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos |
| EP2054418B1 (en) | 2006-07-06 | 2011-11-09 | Array Biopharma Inc. | Dihydrothieno pyrimidines as akt protein kinase inhibitors |
| BRPI0713555A2 (pt) | 2006-07-06 | 2012-03-20 | Array Biopharma, Inc. | ciclopenta [d] pirimidinas como inibidores de akt protéina cinase |
| US8329701B2 (en) | 2006-07-06 | 2012-12-11 | Array Biopharma Inc. | Dihydrofuro pyrimidines as AKT protein kinase inhibitors |
| US8063050B2 (en) | 2006-07-06 | 2011-11-22 | Array Biopharma Inc. | Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CN111643496A (zh) | 2006-12-14 | 2020-09-11 | 埃克塞利希斯股份有限公司 | 使用mek抑制剂的方法 |
| US8846683B2 (en) | 2007-07-05 | 2014-09-30 | Array Biopharma, Inc. | Pyrimidyl cyclopentanes as Akt protein kinase inhibitors |
| US9409886B2 (en) | 2007-07-05 | 2016-08-09 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| AU2008272830B8 (en) | 2007-07-05 | 2013-12-12 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as AKT protein kinase inhibitors |
| CA2692506C (en) | 2007-07-05 | 2015-11-24 | Array Biopharma Inc. | Pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| EP2203411B1 (en) | 2007-09-20 | 2016-01-06 | Ramot at Tel-Aviv University Ltd. | N-phenyl anthranilic acid derivatives and uses thereof |
| NZ586418A (en) | 2007-12-19 | 2012-09-28 | Cancer Rec Tech Ltd | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
| NZ586346A (en) | 2008-01-09 | 2012-02-24 | Array Biopharma Inc | Hydroxylated pyrimidyl cyclopentanes as akt protein kinase inhibitors |
| MX2010007546A (es) | 2008-01-09 | 2010-09-30 | Array Biopharma Inc | Pirimidil ciclopentanos hidroxilados en forma de inhibidores de akt proteína quinasa. |
| WO2010051933A2 (en) | 2008-11-10 | 2010-05-14 | Bayer Schering Pharma Aktiengesellschaft | Substituted sulphonamido phenoxybenzamides |
| WO2011047796A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Schering Pharma Aktiengesellschaft | Substituted halophenoxybenzamide derivatives |
| CA2777430A1 (en) | 2009-10-21 | 2011-04-28 | Bayer Pharma Aktiengesellschaft | Substituted benzosulphonamides |
| JP2013508318A (ja) | 2009-10-21 | 2013-03-07 | バイエル・ファルマ・アクチェンゲゼルシャフト | 置換されたベンゾスルホンアミド誘導体 |
| WO2011092469A1 (en) | 2010-02-01 | 2011-08-04 | Cancer Research Technology Limited | 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy |
| WO2012055953A1 (en) | 2010-10-29 | 2012-05-03 | Bayer Pharma Aktiengesellschaft | Substituted phenoxypyridines |
| CN103841976A (zh) | 2011-04-01 | 2014-06-04 | 基因泰克公司 | Akt和mek抑制剂化合物的组合及其使用方法 |
| HUE036513T2 (hu) | 2011-04-01 | 2018-07-30 | Genentech Inc | AKT inhibitor vegyület és abirateron kombinációja terápiás kezelésekben való alkalmazásra |
| CN104837826B (zh) | 2012-10-12 | 2018-07-27 | 埃克塞里艾克西斯公司 | 制备用于治疗癌症的化合物的新型方法 |
| JP6863742B2 (ja) * | 2013-09-11 | 2021-04-21 | ジ・アドミニストレーターズ・オブ・ザ・チューレーン・エデュケーショナル・ファンド | 新規アントラニルアミドとその使用 |
| GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
| CA3001879A1 (en) | 2015-10-27 | 2017-05-04 | Acetylon Pharmaceuticals, Inc. | Hdac inhibitors for the treatment of diabetic peripheral neuropathy |
| SI3697405T1 (sl) | 2017-10-17 | 2021-11-30 | Atriva Therapeutics Gmbh | Novi zaviralec MEK za zdravljenje virusnih in bakterijskih okužb |
| CA3140704A1 (en) * | 2019-06-28 | 2020-12-30 | Petrine WELLENDORPH | Treatment of cns disorders with sleep disturbances |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU5610398A (en) * | 1997-02-28 | 1998-09-18 | Warner-Lambert Company | Method of treating or preventing septic shock by administering a mek inhibitor |
| ATE344791T1 (de) * | 1997-07-01 | 2006-11-15 | Warner Lambert Co | 2-(4-brom or 4-iod phenylamino)benzoesäurederivate und ihre anwendung als mek-inhibitoren |
| HUP0003731A3 (en) * | 1997-07-01 | 2002-11-28 | Warner Lambert Co | 4-bromo or 4-iodo phenylamino benzhydroxamic acid derivatives and their use as mek inhibitors |
| JP2002532415A (ja) * | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Ｍｅｋ阻害剤による関節炎の治療 |
-
2000
- 2000-07-05 TR TR2002/00082T patent/TR200200082T2/xx unknown
- 2000-07-05 EP EP00943383A patent/EP1202726A2/en not_active Withdrawn
- 2000-07-05 CN CN00809801A patent/CN1373660A/zh active Pending
- 2000-07-05 CA CA002374052A patent/CA2374052A1/en not_active Abandoned
- 2000-07-05 WO PCT/US2000/018347 patent/WO2001005392A2/en not_active Application Discontinuation
- 2000-07-05 IL IL14761900A patent/IL147619A0/xx unknown
- 2000-07-05 AU AU57860/00A patent/AU5786000A/en not_active Abandoned
- 2000-07-05 NZ NZ515567A patent/NZ515567A/xx unknown
- 2000-07-05 JP JP2001510449A patent/JP2003504400A/ja active Pending
- 2000-07-05 HU HU0202623A patent/HUP0202623A3/hu unknown
- 2000-07-05 PL PL00352684A patent/PL352684A1/xx not_active Application Discontinuation
- 2000-07-05 KR KR1020027000609A patent/KR20020012315A/ko not_active Application Discontinuation
- 2000-07-13 AR ARP000103604A patent/AR024732A1/es unknown
- 2000-07-14 PE PE2000000705A patent/PE20010545A1/es not_active Application Discontinuation
- 2000-07-14 CO CO00053304A patent/CO5300398A1/es not_active Application Discontinuation
-
2001
- 2001-11-30 ZA ZA200109907A patent/ZA200109907B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001005392A3 (en) | 2001-07-19 |
| PE20010545A1 (es) | 2001-06-04 |
| NZ515567A (en) | 2004-03-26 |
| TR200200082T2 (tr) | 2002-04-22 |
| AU5786000A (en) | 2001-02-05 |
| CA2374052A1 (en) | 2001-01-25 |
| AR024732A1 (es) | 2002-10-23 |
| CN1373660A (zh) | 2002-10-09 |
| KR20020012315A (ko) | 2002-02-15 |
| WO2001005392A2 (en) | 2001-01-25 |
| IL147619A0 (en) | 2002-08-14 |
| EP1202726A2 (en) | 2002-05-08 |
| HUP0202623A2 (hu) | 2002-11-28 |
| JP2003504400A (ja) | 2003-02-04 |
| PL352684A1 (en) | 2003-09-08 |
| HUP0202623A3 (en) | 2003-03-28 |
| ZA200109907B (en) | 2003-02-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO5300398A1 (es) | Metodo para el tratamiento del dolor cronico mediante la utilizacion de inhibidores mek | |
| CO5150150A1 (es) | 4-oxo-1,4-dihidro-3-quinoleincarboxamidas como agentes antivirales | |
| EA200401284A1 (ru) | Замещённые бензазолы и их применение в качестве ингибиторов киназы raf | |
| AR016762A1 (es) | Compuestos del acido 4-bromo o 4-yodo fenilamino benzohidroxamico, formulaciones farmaceuticas y uso del mismo | |
| PE20020585A1 (es) | Inhibidores de metaloproteinasa del tipo pirimidin-2,4,6-triona | |
| EA200300354A1 (ru) | Хинолиноновые производные в качестве ингибиторов тирозинкиназы | |
| DE69523169D1 (de) | Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung | |
| EA200300323A1 (ru) | ПРОИЗВОДНЫЕ ГУАНИДИНОБЕНЗАМИДА (ВАРИАНТЫ), КОМПОЗИЦИЯ (ВАРИАНТЫ), СПОСОБ ЛЕЧЕНИЯ ОПОСРЕДОВАННОГО mc4-r ЗАБОЛЕВАНИЯ (ВАРИАНТЫ) | |
| FI964772A (fi) | (a)-annelloidut pyrrolijohdannaiset ja niiden käyttö farmasiassa | |
| BR9608048A (pt) | Compostos de benzimidazol, composições farmacêuticas contendo os compostos e seu uso. | |
| CO5060482A1 (es) | Derivados terapeuticos de biarilo | |
| EA199800909A1 (ru) | Тригидрат мезилата 5-(2-(4-(1,2-бензизотиазол-3-ил)пиперазин-1-ил)этил)-6-хлор-1,3-дигидро-2н-индол-2-она, фармацевтическая композиция и способ лечения психического расстройства | |
| DE60039729D1 (de) | N-(8,8,8-Trifluorooctyl)-1,5-dideoxy-1,5-imino-D-glucitol zur Behandlung von Hepatitis-Virus-Infektionen | |
| EA201001081A1 (ru) | Соединения тетрациклина, фармацевтическая композиция и способ лечения чувствительного к тетрациклину состояния у субъекта | |
| AR015765A1 (es) | Dihidropirimidinas 2 heterociclicamente sustituidas, proceso para su preparacion, medicamentos que los contienen, proceso para la preparacion de los mismosuso de dichos dihidropirimidinas para la preparacion de un medicamento. | |
| CO5251464A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2- tiazolil)-carboxamida de cinasas dependientes de ciclina | |
| BR9307580A (pt) | Compostos processo para a preparação dos mesmos composições farmacêuticas uso de um composto e processo de tratamento de um mamífero que inclui o ser humano | |
| TR199701219T1 (xx) | Benzimidazol bile�ikleri, bu bile�ikleri i�eren ispen�iyar� bile�ikler. | |
| CO5180605A1 (es) | Compuestos de indol | |
| DE60105025D1 (de) | Pharmazeutische verbindungen zur behandlung von chronisch-obstruktiver bronchopneumonie | |
| CO5261565A1 (es) | Inhibidores de n-(5-(((5-alquil-2-oxazolil)metil)tio)-2-tiazolil)-carboxamida de cinasas dependientes de ciclina | |
| ES2119094T3 (es) | Inhibicion de la hemorragia uterina disfuncional. | |
| DK0920426T3 (da) | Hidtil ukendte thiazolderivater med phosphodiesteraseinhiberende virkning | |
| EA200200596A1 (ru) | Окс (ади) азолилгидроксамовые кислоты, полезные в качестве ингибиторов проколлаген-с-протеиназы | |
| RU2008108903A (ru) | Пентациклический ингибитор киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Application refused |